It has been demonstrated that the mTOR inhibitor rapamycin can activate the TGF-β receptor via a mechanism independent of TGF-β, while maintaining its inhibitory effect on mTOR, ultimately leading to the suppression of tumor cell proliferation [38]. The gene discussed is TGFB1; the disease is neoplasm.